- 23.4k views
Anticoagulants in CVD
The financial burden of thrombotic events in cardiovascular disease is enormous. Anticoagulant medication is advised for the treatment and secondary prevention of acute coronary syndrome as well as the prevention of thrombotic events in numerous cardiovascular disorders, such as stroke in atrial fibrillation. Present-day parenteral anticoagulants consist of fondaparinux, low-molecular-weight heparins (LMWHs), and unfractionated heparin. When admitted to the hospital, patients with acute coronary syndrome are typically given either unfractionated heparin or a low-molecular weight heparin (LMWH). Both treatments are equally effective in lowering the risk of death and myocardial infarction, although LMWHs may be safer and don't need to be monitored for blood clotting. Using fondaparinux reduces mortality from acute coronary syndrome considerably when compared to LMWHs or unfractionated heparin. However, long-term outpatient usage of parenteral medications is inconvenient. The only oral anticoagulants available at this time are vitamin K antagonists. A large unmet need exists for new convenient and well-tolerated oral anticoagulants that do not require routine monitoring.
About the Speaker
Dr. Abhishek Tiwari
Consultant Interventional Cardiologist, Ahalia Hospital, Coimbatore
Dr. Abhishek Tiwari, Consultant Interventional Cardiologist, Ahalia Hospital, Coimbatore
Upcoming Case Discussions
Clinical AI Prediction Tools: Opportunities, Barriers, and the Road to Adoption
Clinical AI prediction tools offer significant opportunities to enhance patient care by providing early insights into potential health risks, improving diagnostic accuracy, and enabling personalized treatment plans. These tools can analyze large datasets, including medical history, genetic information, and real-time patient data, to predict outcomes such as disease progression or response to treatment. However, challenges such as data privacy concerns, the need for high-quality datasets, and integration with existing healthcare systems pose barriers to widespread adoption. Additionally, regulatory hurdles and ensuring clinician trust in AI-driven recommendations are critical factors for successful implementation. Overcoming these challenges requires collaboration between healthcare providers, AI developers, and regulatory bodies to ensure these tools are both effective and safe.
Endometriosis and Infertility
Endometriosis is a condition where tissue similar to the lining of the uterus grows outside of it, often affecting the ovaries, fallopian tubes, and pelvic organs. This disorder can cause painful periods, pelvic pain, and, in many cases, infertility. The presence of endometrial-like tissue outside the uterus can disrupt normal reproductive function by causing inflammation, scarring, and adhesions, which can interfere with ovulation, fertilization, and embryo implantation. Approximately 30-50% of women with endometriosis experience infertility, making it one of the leading causes of reproductive challenges in affected individuals. However, treatment options like surgery, medication, or assisted reproductive technologies can help improve fertility outcomes.
Impact of Endometriosis on Fertility
Endometriosis, a condition where endometrial-like tissue grows outside the uterus, can significantly impact fertility. It causes inflammation, scarring, and adhesions that may distort pelvic anatomy, block fallopian tubes, and impair ovarian function. Endometriosis is also linked to hormonal imbalances and poor egg quality, reducing the chances of conception. Symptoms like chronic pelvic pain and painful intercourse further complicate fertility. Diagnosis often requires laparoscopy, while management includes pain relief, hormonal therapy, and assisted reproductive techniques like IVF. Early intervention with medical or surgical treatment can improve reproductive outcomes, but severe cases may necessitate advanced fertility treatments for conception.
Hyperlipidemia: From Diagnosis to Treatment
Hyperlipidemia is a condition characterized by elevated levels of lipids, such as cholesterol and triglycerides, in the blood, which can increase the risk of cardiovascular diseases. Diagnosis typically involves blood tests measuring lipid profiles, while treatment focuses on lifestyle changes, such as diet and exercise, alongside medications like statins to manage cholesterol levels and reduce cardiovascular risk. Regular monitoring is essential for effective management and prevention of complications.
Acne: Disorders and Treatment Approaches
Acne is a common dermatological condition caused by clogged pores, excess sebum production, bacterial growth, and inflammation. It can manifest as blackheads, whiteheads, papules, pustules, or cysts, often leading to scarring if untreated. Various factors, including hormonal changes, diet, stress, and genetics, influence its severity. Treatment approaches range from topical and oral medications, such as retinoids, antibiotics, and hormonal therapy, to advanced procedures like chemical peels and laser therapy. A personalized skincare regimen, along with lifestyle modifications, plays a crucial role in managing and preventing acne.
Author Post
Impact
+
Talks
+
webinar
+
no.of registrations
One liner about speaker
Why is speaker relevant?
Dr. Abhishek Tiwari's Talks on Assimilate
- 12th -Sep-2024, TIME : 5:00PM TO 6:00 PM
- 0
The financial burden of thrombotic events in cardiovascular disease is enormous. Anticoagulant medication is advised for the treatment and secondary prevention of acute coronary syndrome as well as the prevention of thrombotic events in numerous cardiovascular disorders, such as stroke in atrial fibrillation. Present-day parenteral anticoagulants consist of fondaparinux, low-molecular-weight heparins (LMWHs), and unfractionated heparin. When admitted to the hospital, patients with acute coronary syndrome are typically given either unfractionated heparin or a low-molecular weight heparin (LMWH). Both treatments are equally effective in lowering the risk of death and myocardial infarction, although LMWHs may be safer and don't need to be monitored for blood clotting. Using fondaparinux reduces mortality from acute coronary syndrome considerably when compared to LMWHs or unfractionated heparin. However, long-term outpatient usage of parenteral medications is inconvenient. The only oral anticoagulants available at this time are vitamin K antagonists. A large unmet need exists for new convenient and well-tolerated oral anticoagulants that do not require routine monitoring.